{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:25:32Z","timestamp":1793316332151,"version":"4.5.0"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013822","name":"Kurdistan University Of Medical Sciences","doi-asserted-by":"publisher","award":["IR.MUK.REC.1401.380"],"award-info":[{"award-number":["IR.MUK.REC.1401.380"]}],"id":[{"id":"10.13039\/501100013822","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.intimp.2023.110032","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T20:01:10Z","timestamp":1678996870000},"page":"110032","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated"],"prefix":"10.1016","volume":"118","author":[{"given":"Arian","family":"Charehjoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Majidpoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2004-3465","authenticated-orcid":false,"given":"Keywan","family":"Mortezaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2023.110032_b0005","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.neo.2017.12.002","article-title":"A longitudinal analysis of IDO and PDL1 expression during immune-or targeted therapy in advanced melanoma","volume":"20","author":"Kr\u00e4henb\u00fchl","year":"2018","journal-title":"Neoplasia"},{"key":"10.1016\/j.intimp.2023.110032_b0010","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.4659","article-title":"Checkpoint inhibitor\/interleukin-based combination therapy of cancer","author":"Mortezaee","year":"2022","journal-title":"Cancer Med."},{"issue":"3","key":"10.1016\/j.intimp.2023.110032_b0015","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1245\/s10434-019-07878-8","article-title":"High stromal TGFBI in lung cancer and intratumoral CD8-positive T cells were associated with poor prognosis and therapeutic resistance to immune checkpoint inhibitors","volume":"27","author":"Nakazawa","year":"2020","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110032_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-28437-y","article-title":"Development and validation of a prognostic and predictive 32-gene signature for gastric cancer","volume":"13","author":"Cheong","year":"2022","journal-title":"Nat. Commun."},{"issue":"652","key":"10.1016\/j.intimp.2023.110032_b0025","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aax4585","article-title":"Breast cancer\u2013associated macrophages promote tumorigenesis by suppressing succinate dehydrogenase in tumor cells","volume":"13","author":"G\u00f3mez","year":"2020","journal-title":"Sci. Signal."},{"key":"10.1016\/j.intimp.2023.110032_b0030","series-title":"The impact of tumor hypoxia on the clinical efficacy of anti-PD-1 mAb treatment in recurrent\/metastatic HNSCC patients (R\/M)","author":"Zandberg","year":"2020"},{"issue":"1","key":"10.1016\/j.intimp.2023.110032_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01102-5","article-title":"The relationship between expression of PD-L1 and HIF-1\u03b1 in glioma cells under hypoxia","volume":"14","author":"Ding","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2023.110032_b0040","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41556-020-0562-4","article-title":"Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy","volume":"22","author":"Gao","year":"2020","journal-title":"Nat. Cell Biol."},{"issue":"5","key":"10.1016\/j.intimp.2023.110032_b0045","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm.4308","article-title":"VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer","volume":"23","author":"Gao","year":"2017","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.intimp.2023.110032_b0050","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/modpathol.2017.89","article-title":"Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients","volume":"30","author":"Kakavand","year":"2017","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.intimp.2023.110032_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121083","article-title":"VISTA immune regulatory effects in bypassing cancer immunotherapy","author":"Mortezaee","year":"2022","journal-title":"Updated. Life Sciences"},{"issue":"1","key":"10.1016\/j.intimp.2023.110032_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2051-1426-2-3","article-title":"Mechanism of tumor rejection with doublets of CTLA-4, PD-1\/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment","volume":"2","author":"Spranger","year":"2014","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2023.110032_b0065","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune EscapeLAG-3 and PD-1 Synergistically Prevent Antitumor Immunity","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res."},{"issue":"19_Supplement","key":"10.1016\/j.intimp.2023.110032_b0070","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1158\/1538-7445.AM2014-5023","article-title":"Synergistic antitumor effects of combinatorial immune checkpoint inhibition with anti-PD-1\/PD-L antibodies and the IDO pathway inhibitors NLG-919 and indoximod in the context of active immunotherapy","volume":"74","author":"Mautino","year":"2014","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2023.110032_b0075","first-page":"1","article-title":"Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models","volume":"3","author":"Spahn","year":"2015","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2023.110032_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-024-52768-7","article-title":"An in situ hydrogel-mediated chemo-immunometabolic cancer therapy","volume":"13","author":"Wang","year":"2022","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.intimp.2023.110032_b0085","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/cbin.11506","article-title":"Redox tolerance and metabolic reprogramming in solid tumors","volume":"45","author":"Mortezaee","year":"2021","journal-title":"Cell Biol. Int."},{"issue":"10","key":"10.1016\/j.intimp.2023.110032_b0090","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1002\/cbin.11655","article-title":"Normalization in tumor ecosystem: Opportunities and challenges","volume":"45","author":"Mortezaee","year":"2021","journal-title":"Cell Biol. Int."},{"issue":"11","key":"10.1016\/j.intimp.2023.110032_b0095","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1016\/j.molcel.2021.03.019","article-title":"Immune-regulated IDO1-dependent tryptophan metabolism is source of one-carbon units for pancreatic cancer and stellate cells","volume":"81","author":"Newman","year":"2021","journal-title":"Mol. Cell"},{"issue":"2","key":"10.1016\/j.intimp.2023.110032_b0100","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.cell.2021.12.023","article-title":"Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma","volume":"185","author":"Risom","year":"2022","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2023.110032_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-30436-y","article-title":"Multifunctional metal-organic framework-based nanoreactor for starvation\/oxidation improved indoleamine 2, 3-dioxygenase-blockade tumor immunotherapy","volume":"13","author":"Dai","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2023.110032_b0110","doi-asserted-by":"crossref","first-page":"vi380","DOI":"10.1093\/annonc\/mdw379.06","article-title":"Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: updated phase 1 results from ECHO-202\/KEYNOTE-037","volume":"27","author":"Gangadhar","year":"2016","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110032_b0115","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.immuni.2017.01.005","article-title":"A relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells","volume":"46","author":"Mondanelli","year":"2017","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2023.110032_b0120","doi-asserted-by":"crossref","first-page":"E62","DOI":"10.1073\/pnas.1711373114","article-title":"In vivo inhibition of tryptophan catabolism reorganizes the tuberculoma and augments immune-mediated control of Mycobacterium tuberculosis","volume":"115","author":"Gautam","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2023.110032_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110800","article-title":"A pan-cancer metabolic atlas of the tumor microenvironment","volume":"39","author":"Rohatgi","year":"2022","journal-title":"Cell Rep."},{"issue":"51","key":"10.1016\/j.intimp.2023.110032_b0130","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/S0959-8049(16)30312-4","article-title":"511 Updated results from a phase 1\/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma","volume":"3","author":"Gibney","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.intimp.2023.110032_b0135","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nm934","article-title":"Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase","volume":"9","author":"Uyttenhove","year":"2003","journal-title":"Nat. Med."},{"issue":"17","key":"10.1016\/j.intimp.2023.110032_b0140","first-page":"3520","article-title":"Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity","volume":"115","author":"Liu","year":"2010","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"3","key":"10.1016\/j.intimp.2023.110032_b0145","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nm1196","article-title":"Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy","volume":"11","author":"Muller","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2023.110032_b0150","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.omtm.2020.12.013","article-title":"Inhibition of indoleamine 2, 3-dioxygenase 1 synergizes with oxaliplatin for efficient colorectal cancer therapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol. Therapy-Methods Clin. Developm."},{"issue":"1","key":"10.1016\/j.intimp.2023.110032_b0155","first-page":"1","article-title":"Catalytical nano-immunocomplexes for remote-controlled sono-metabolic checkpoint trimodal cancer therapy","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2023.110032_b0160","first-page":"1","article-title":"Metabolomic adaptations and correlates of survival to immune checkpoint blockade","volume":"10","author":"Li","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2023.110032_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114150","article-title":"Bypassing anti-PD-(L) 1 therapy: Mechanisms and management strategies","volume":"158","author":"Mortezaee","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2023.110032_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113906","article-title":"Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy","volume":"156","author":"Rouzbahani","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"12","key":"10.1016\/j.intimp.2023.110032_b0175","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12032-022-01837-2","article-title":"Extracellular vesicle-based checkpoint regulation and immune state in cancer","volume":"39","author":"Mortezaee","year":"2022","journal-title":"Med. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110032_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-25865-0","article-title":"Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy","volume":"12","author":"Takamatsu","year":"2021","journal-title":"Nat. Commun."},{"issue":"6411","key":"10.1016\/j.intimp.2023.110032_b0185","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.intimp.2023.110032_b0190","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1038\/s41591-021-01544-x","article-title":"A phase 1\/2 trial of an immune-modulatory vaccine against IDO\/PD-L1 in combination with nivolumab in metastatic melanoma","volume":"27","author":"Kjeldsen","year":"2021","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.110032_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-27620-x","article-title":"Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response","volume":"12","author":"Yen","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2023.110032_b0200","first-page":"1","article-title":"Precision cancer sono-immunotherapy using deep-tissue activatable semiconducting polymer immunomodulatory nanoparticles","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2023.110032_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-01725-8","article-title":"Structural insights into substrate and inhibitor binding sites in human indoleamine 2, 3-dioxygenase 1","volume":"8","author":"Lewis-Ballester","year":"2017","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.intimp.2023.110032_b0210","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41591-019-0404-8","article-title":"The landscape of cancer cell line metabolism","volume":"25","author":"Li","year":"2019","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.intimp.2023.110032_b0215","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.immuni.2022.01.006","article-title":"Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity","volume":"55","author":"Hezaveh","year":"2022","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2023.110032_b0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-28509-z","article-title":"Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer","volume":"13","author":"Singh","year":"2022","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.intimp.2023.110032_b0225","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1158\/1078-0432.CCR-18-2740","article-title":"Phase I Study of the Indoleamine 2, 3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid TumorsNavoximod and Atezolizumab in Advanced Solid Tumors","volume":"25","author":"Jung","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.intimp.2023.110032_b0230","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s43018-021-00201-z","article-title":"Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas","volume":"2","author":"Friedrich","year":"2021","journal-title":"Nature Cancer"},{"issue":"8","key":"10.1016\/j.intimp.2023.110032_b0235","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nbt.4180","article-title":"Reversal of indoleamine 2, 3-dioxygenase\u2013mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme","volume":"36","author":"Triplett","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"13_Supplement","key":"10.1016\/j.intimp.2023.110032_b0240","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1158\/1538-7445.AM2019-4454","article-title":"Identification of BAY-218, a potent and selective small-molecule AhR inhibitor, as a new modality to counteract tumor immunosuppression","volume":"79","author":"Schmees","year":"2019","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.intimp.2023.110032_b0245","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.molmed.2021.07.006","article-title":"The kynurenine pathway in chronic diseases: a compensatory mechanism or a driving force?","volume":"27","author":"Joisten","year":"2021","journal-title":"Trends Mol. Med."},{"issue":"686","key":"10.1016\/j.intimp.2023.110032_b0250","doi-asserted-by":"crossref","first-page":"eabc7405","DOI":"10.1126\/scisignal.abc7405","article-title":"Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics","volume":"14","author":"Daniels","year":"2021","journal-title":"Sci. Signal."},{"issue":"32","key":"10.1016\/j.intimp.2023.110032_b0255","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1200\/JCO.2018.78.9602","article-title":"Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I\/II trial (ECHO-202\/KEYNOTE-037)","volume":"36","author":"Mitchell","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2023.110032_b0260","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bjd.13100","article-title":"Peritumoral indoleamine 2, 3-dioxygenase expression in melanoma: an early marker of resistance to immune control?","volume":"171","author":"Chevolet","year":"2014","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2023.110032_b0265","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2005.03.013","article-title":"GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2, 3-dioxygenase","volume":"22","author":"Munn","year":"2005","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.intimp.2023.110032_b0270","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/sj.cdd.4401073","article-title":"T cell apoptosis by tryptophan catabolism","volume":"9","author":"Fallarino","year":"2002","journal-title":"Cell Death Differ."},{"issue":"26","key":"10.1016\/j.intimp.2023.110032_b0275","first-page":"eabl8247","article-title":"In vivo multidimensional CRISPR screens identify Lgals2 as an immunotherapy target in triple-negative breast cancer. Science","volume":"8","author":"Ji","year":"2022","journal-title":"Advances"},{"issue":"3","key":"10.1016\/j.intimp.2023.110032_b0280","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41590-020-00850-9","article-title":"IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor","volume":"22","author":"Liu","year":"2021","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110032_b0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-01651-9","article-title":"Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression","volume":"8","author":"Lu","year":"2017","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.intimp.2023.110032_b0290","doi-asserted-by":"crossref","first-page":"eabd9738","DOI":"10.1126\/sciadv.abd9738","article-title":"Decoding the multicellular ecosystem of lung adenocarcinoma manifested as pulmonary subsolid nodules by single-cell RNA sequencing","volume":"7","author":"Xing","year":"2021","journal-title":"Sci. Adv."},{"issue":"7","key":"10.1016\/j.intimp.2023.110032_b0295","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.4049\/jimmunol.172.7.4100","article-title":"Ligation of B7\u20131\/B7-2 by human CD4+ T cells triggers indoleamine 2, 3-dioxygenase activity in dendritic cells","volume":"172","author":"Munn","year":"2004","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110032_b0300","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1084\/jem.20020052","article-title":"Inhibition of allogeneic T cell proliferation by indoleamine 2, 3-dioxygenase\u2013expressing dendritic cells: mediation of suppression by tryptophan metabolites","volume":"196","author":"Terness","year":"2002","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.intimp.2023.110032_b0305","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/ni.2077","article-title":"Indoleamine 2, 3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells","volume":"12","author":"Pallotta","year":"2011","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2023.110032_b0310","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1016\/j.immuni.2021.09.005","article-title":"Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity","volume":"54","author":"Sharma","year":"2021","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.intimp.2023.110032_b0315","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.immuni.2021.07.007","article-title":"Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease","volume":"54","author":"Mulder","year":"2021","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.intimp.2023.110032_b0320","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.4049\/jimmunol.1100164","article-title":"Activated CD69+ T cells foster immune privilege by regulating IDO expression in tumor-associated macrophages","volume":"188","author":"Zhao","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2023.110032_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119627","article-title":"Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives","volume":"277","author":"Mortezaee","year":"2021","journal-title":"Life Sci."},{"issue":"5","key":"10.1016\/j.intimp.2023.110032_b0330","first-page":"750","article-title":"CLL-cells induce IDOhi CD14+ HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs","volume":"124","author":"Jitschin","year":"2014","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"7845","key":"10.1016\/j.intimp.2023.110032_b0335","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41586-020-03054-1","article-title":"Anti-tumour immunity induces aberrant peptide presentation in melanoma","volume":"590","author":"Bartok","year":"2021","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.intimp.2023.110032_b0340","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.ejca.2011.09.007","article-title":"Indoleamine 2, 3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients","volume":"48","author":"Speeckaert","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2023.110032_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109071","article-title":"Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy","volume":"35","author":"DeVito","year":"2021","journal-title":"Cell Rep."},{"issue":"7508","key":"10.1016\/j.intimp.2023.110032_b0350","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nature13323","article-title":"Aryl hydrocarbon receptor control of a disease tolerance defence pathway","volume":"511","author":"Bessede","year":"2014","journal-title":"Nature"},{"issue":"28","key":"10.1016\/j.intimp.2023.110032_b0355","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1038\/onc.2009.104","article-title":"Aryl hydrocarbon receptor inhibition downregulates the TGF-\u03b2\/Smad pathway in human glioblastoma cells","volume":"28","author":"Gramatzki","year":"2009","journal-title":"Oncogene"},{"issue":"25","key":"10.1016\/j.intimp.2023.110032_b0360","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1038\/onc.2015.387","article-title":"The aryl hydrocarbon receptor links integrin signaling to the TGF-\u03b2 pathway","volume":"35","author":"Silginer","year":"2016","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.intimp.2023.110032_b0365","doi-asserted-by":"crossref","first-page":"e005543","DOI":"10.1136\/jitc-2022-005543","article-title":"Anti-TGF-\u03b2\/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer","volume":"10","author":"Yi","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2023.110032_b0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01045-x","article-title":"The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-\u03b2 and PD-L1","volume":"14","author":"Yi","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2023.110032_b0375","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/253191","article-title":"PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response","author":"Trabanelli","year":"2015","journal-title":"J. Immunol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2023.110032_b0380","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1182\/blood-2005-08-3507","article-title":"CD25 and indoleamine 2, 3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition","volume":"108","author":"von Bergwelt-Baildon","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2023.110032_b0385","doi-asserted-by":"crossref","first-page":"1896643","DOI":"10.1080\/2162402X.2021.1896643","article-title":"Combination of EP4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells","volume":"10","author":"Wang","year":"2021","journal-title":"Oncoimmunology"},{"issue":"52","key":"10.1016\/j.intimp.2023.110032_b0390","doi-asserted-by":"crossref","first-page":"89802","DOI":"10.18632\/oncotarget.21155","article-title":"Prostaglandin E2 and PD-1 mediated inhibition of antitumor CTL responses in the human tumor microenvironment","volume":"8","author":"Miao","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.intimp.2023.110032_b0395","first-page":"1","article-title":"Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.intimp.2023.110032_b0400","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20130066","article-title":"Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4","volume":"210","author":"Holmgaard","year":"2013","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.intimp.2023.110032_b0405","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/ni846","article-title":"CTLA-4\u2013Ig regulates tryptophan catabolism in vivo","volume":"3","author":"Grohmann","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2023.110032_b0410","series-title":"IDO1 as a mechanism of adaptive immune resistance to anti-PD1 monotherapy in HNSCC","author":"Wirth","year":"2017"},{"key":"10.1016\/j.intimp.2023.110032_b0415","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.omtn.2022.04.034","article-title":"Immunogenomic landscape analyses of immune molecule signature-based risk panel for patients with triple-negative breast cancer","volume":"28","author":"Liu","year":"2022","journal-title":"Molecular Therapy-Nucleic Acids"},{"issue":"1","key":"10.1016\/j.intimp.2023.110032_b0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-23995-z","article-title":"Tumor-associated hematopoietic stem and progenitor cells positively linked to glioblastoma progression","volume":"12","author":"Lu","year":"2021","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.intimp.2023.110032_b0425","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1021\/jacs.9b12232","article-title":"Modularly designed peptide nanoprodrug augments antitumor immunity of PD-L1 checkpoint blockade by targeting indoleamine 2, 3-dioxygenase","volume":"142","author":"Han","year":"2020","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.intimp.2023.110032_b0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-17750-z","article-title":"Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine","volume":"11","author":"Campesato","year":"2020","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.intimp.2023.110032_b0435","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ccell.2018.02.005","article-title":"Tumor-repopulating cells induce PD-1 expression in CD8+ T cells by transferring kynurenine and AhR activation","volume":"33","author":"Liu","year":"2018","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.intimp.2023.110032_b0440","doi-asserted-by":"crossref","first-page":"e1500845","DOI":"10.1126\/sciadv.1500845","article-title":"The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment","volume":"1","author":"Sharma","year":"2015","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.intimp.2023.110032_b0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-024-52768-7","article-title":"The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy","volume":"10","author":"Wang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2023.110032_b0450","doi-asserted-by":"crossref","unstructured":"Sato, E., S.H. Olson, J. Ahn, et al., Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proceedings of the National Academy of Sciences, 2005. 102(51): p. 18538-18543.","DOI":"10.1073\/pnas.0509182102"},{"key":"10.1016\/j.intimp.2023.110032_b0455","doi-asserted-by":"crossref","unstructured":"Spranger, S., R.M. Spaapen, Y. Zha, et al., Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Science translational medicine, 2013. 5(200): p. 200ra116-200ra116.","DOI":"10.1126\/scitranslmed.3006504"},{"key":"10.1016\/j.intimp.2023.110032_b0460","doi-asserted-by":"crossref","unstructured":"Siu, L.L., K. Gelmon, Q. Chu, et al., Abstract CT116: BMS-986205, an optimized indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1\/2a trial. Cancer Research, 2017. 77(13_Supplement): p. CT116-CT116.","DOI":"10.1158\/1538-7445.AM2017-CT116"},{"key":"10.1016\/j.intimp.2023.110032_b0465","doi-asserted-by":"crossref","unstructured":"Beatty, G.L., P.J. O'Dwyer, J. Clark, et al., Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2, 3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies. 2013, American Society of Clinical Oncology.","DOI":"10.1200\/jco.2013.31.15_suppl.3025"},{"issue":"5","key":"10.1016\/j.intimp.2023.110032_b0470","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1021\/acsmedchemlett.6b00391","article-title":"INCB24360 (Epacadostat), a highly potent and selective indoleamine-2, 3-dioxygenase 1 (IDO1) inhibitor for immuno-oncology","volume":"8","author":"Yue","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"issue":"13","key":"10.1016\/j.intimp.2023.110032_b0475","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1158\/1078-0432.CCR-16-2272","article-title":"First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2, 3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid MalignanciesIDO1 Inhibitor in Advanced Solid Cancers","volume":"23","author":"Beatty","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2023.110032_b0480","first-page":"1","article-title":"Bioorthogonal in situ assembly of nanomedicines as drug depots for extracellular drug delivery","volume":"13","author":"Cao","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2023.110032_b0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0351-9","article-title":"Phase Ia study of the indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors","volume":"6","author":"Nayak-Kapoor","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2023.110032_b0490","doi-asserted-by":"crossref","unstructured":"Zakharia, Y., R. McWilliams, M. Shaheen, et al. Interim analysis of the Phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma. in Cancer Research. 2017. AMER ASSOC CANCER RESEARCH 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA\u2026.","DOI":"10.1158\/1538-7445.AM2017-CT117"},{"key":"10.1016\/j.intimp.2023.110032_b0495","doi-asserted-by":"crossref","first-page":"v428","DOI":"10.1093\/annonc\/mdx377.001","article-title":"Epacadostat plus pembrolizumab in patients with advanced melanoma: phase 1 and 2 efficacy and safety results from ECHO-202\/KEYNOTE-037","volume":"28","author":"Hamid","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2023.110032_b0500","doi-asserted-by":"crossref","unstructured":"Lara, P., T.M. Bauer, O. Hamid, et al., Epacadostat plus pembrolizumab in patients with advanced RCC: Preliminary phase I\/II results from ECHO-202\/KEYNOTE-037. 2017, American Society of Clinical Oncology.","DOI":"10.1200\/JCO.2017.35.15_suppl.4515"},{"key":"10.1016\/j.intimp.2023.110032_b0505","series-title":"Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: Preliminary phase I\/II results of ECHO-202\/KEYNOTE-037","author":"Gangadhar","year":"2017"},{"key":"10.1016\/j.intimp.2023.110032_b0510","series-title":"Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: Preliminary phase I\/II results of ECHO-202\/KEYNOTE-037","author":"Smith","year":"2017"},{"issue":"8","key":"10.1016\/j.intimp.2023.110032_b0515","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2023.110032_b0520","series-title":"Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I\/II results of ECHO-204","author":"Perez","year":"2017"},{"key":"10.1016\/j.intimp.2023.110032_b0525","doi-asserted-by":"crossref","unstructured":"Burris, H.A., M.S. Gordon, M.D. Hellmann, et al., A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors. 2017, American Society of Clinical Oncology.","DOI":"10.1200\/JCO.2017.35.15_suppl.105"},{"key":"10.1016\/j.intimp.2023.110032_b0530","doi-asserted-by":"crossref","unstructured":"Mellemgaard, A., L. Engel-Norregaard, M.H. Andersen, et al., Combination immunotherapy with IDO vaccine and PD-1 inhibitors in advanced NSCLC. 2017, American Society of Clinical Oncology.","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS2610"},{"issue":"2","key":"10.1016\/j.intimp.2023.110032_b0535","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000605","article-title":"Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+ and CD4+ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses","volume":"8","author":"Dey","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2023.110032_b0540","doi-asserted-by":"crossref","unstructured":"Daud, A., M.N. Saleh, J. Hu, et al., Epacadostat plus nivolumab for advanced melanoma: Updated phase 2 results of the ECHO-204 study. 2018, American Society of Clinical Oncology.","DOI":"10.1200\/JCO.2018.36.15_suppl.9511"},{"issue":"3","key":"10.1016\/j.intimp.2023.110032_b0545","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/pcmr.12340","article-title":"PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1\/PD-L 1 clinical trials","volume":"28","author":"Madore","year":"2015","journal-title":"Pigment Cell Melanoma Res."},{"issue":"7484","key":"10.1016\/j.intimp.2023.110032_b0550","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature12820","article-title":"Diet rapidly and reproducibly alters the human gut microbiome","volume":"505","author":"David","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2023.110032_b0555","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1146\/annurev.nutr.22.011602.092259","article-title":"How host-microbial interactions shape the nutrient environment of the mammalian intestine","volume":"22","author":"Hooper","year":"2002","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.intimp.2023.110032_b0560","article-title":"Exploring the modulatory effects of gut microbiota in anti-cancer therapy","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"issue":"6371","key":"10.1016\/j.intimp.2023.110032_b0565","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti\u2013PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"issue":"6371","key":"10.1016\/j.intimp.2023.110032_b0570","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"6264","key":"10.1016\/j.intimp.2023.110032_b0575","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"V\u00e9tizou","year":"2015","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.intimp.2023.110032_b0580","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41591-018-0060-4","article-title":"Genetic deficiency of indoleamine 2, 3-dioxygenase promotes gut microbiota-mediated metabolic health","volume":"24","author":"Laurans","year":"2018","journal-title":"Nat. Med."},{"issue":"566","key":"10.1016\/j.intimp.2023.110032_b0585","doi-asserted-by":"crossref","first-page":"eaba0624","DOI":"10.1126\/scitranslmed.aba0624","article-title":"Aryl hydrocarbon receptor ligand production by the gut microbiota is decreased in celiac disease leading to intestinal inflammation","volume":"12","author":"Lamas","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.intimp.2023.110032_b0590","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s12094-020-02421-8","article-title":"Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer","volume":"23","author":"Karayama","year":"2021","journal-title":"Clin. Transl. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110032_b0595","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41564-020-00831-6","article-title":"Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice","volume":"6","author":"Lee","year":"2021","journal-title":"Nat. Microbiol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110032_b0600","first-page":"445","article-title":"IDO inhibitor synergized with radiotherapy to delay tumor growth by reversing T cell exhaustion","volume":"21","author":"Liu","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.intimp.2023.110032_b0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118051","article-title":"The role of curcumin\/curcuminoids during gastric cancer chemotherapy: a systematic review of non-clinical study","volume":"257","author":"Najafi","year":"2020","journal-title":"Life Sci."},{"issue":"6","key":"10.1016\/j.intimp.2023.110032_b0610","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1074\/jbc.M807328200","article-title":"Curcumin suppresses the induction of indoleamine 2, 3-dioxygenase by blocking the Janus-activated kinase-protein kinase C\u03b4-STAT1 signaling pathway in interferon-\u03b3-stimulated murine dendritic cells","volume":"284","author":"Jeong","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.intimp.2023.110032_b0615","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2174\/1568009619666191019143539","article-title":"Resveratrol as an adjuvant for normal tissues protection and tumor sensitization","volume":"20","author":"Mortezaee","year":"2020","journal-title":"Curr. Cancer Drug Targets"},{"issue":"2","key":"10.1016\/j.intimp.2023.110032_b0620","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.bbrc.2012.12.093","article-title":"Resveratrol suppresses tumor progression via the regulation of indoleamine 2, 3-dioxygenase","volume":"431","author":"Noh","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"636","key":"10.1016\/j.intimp.2023.110032_b0625","doi-asserted-by":"crossref","first-page":"eabg8402","DOI":"10.1126\/scitranslmed.abg8402","article-title":"Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses","volume":"14","author":"Odunsi","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.intimp.2023.110032_b0630","doi-asserted-by":"crossref","first-page":"e22900","DOI":"10.1002\/jbt.22900","article-title":"The current knowledge concerning solid cancer and therapy","volume":"35","author":"Najafi","year":"2021","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110032_b0635","doi-asserted-by":"crossref","first-page":"eaar2766","DOI":"10.1126\/sciadv.aar2766","article-title":"Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles","volume":"4","author":"Ricklefs","year":"2018","journal-title":"Sci. Adv."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923003533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923003533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:59:30Z","timestamp":1761587970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923003533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":127,"alternative-id":["S1567576923003533"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110032","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110032"}}